NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
RINVOQ (upadacitinib) by AbbVie is janus kinase inhibitors [moa]. First approved in 2019.
Drug data last refreshed 15h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RINVOQ (upadacitinib) is an oral Janus Kinase (JAK) inhibitor approved in 2019 for rheumatoid arthritis and other inflammatory conditions. It works by selectively inhibiting JAK enzymes to reduce inflammatory cytokine signaling. The extended-release formulation enables once-daily dosing for improved patient adherence.
$0.976BPart D
Peak11.5 years to LOERINVOQ is at peak market penetration in a large and growing JAK inhibitor category, suggesting stable commercial team size with focus on market defense rather than rapid expansion.
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Started Oct 2026
30 enrolled
JAK1 GOFSTAT1 GOFSTAT3 GOF+2 more
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Started Oct 2026
52 enrolled
EoEEosinophilic EsophagitisEosinophilic Esophagitis (EoE)
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)
Started Sep 2026
900 enrolled
Atopic Dermatitis
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Started Aug 2026
300 enrolled
Severe Alopecia Areata
A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
Started Jul 2026
50 enrolled
Hidradenitis Suppurativa (Acne Inversa)
Worked on RINVOQ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.